Avanos Medical AVNS Acquired in-process research and development
Acquired in-process research and development at other companies
Other financials
Where this comes from
Reported directly by Avanos Medical in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Avanos Medical’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Avanos Medical's acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Avanos Medical's acquired in-process research and development?
- Avanos Medical (AVNS) reported acquired in-process research and development of $5.2M in Q1 2026.
- How has Avanos Medical's acquired in-process research and development changed year-over-year?
- Avanos Medical's acquired in-process research and development decreased by 3.7% year-over-year, from $5.4M to $5.2M.
- What is the long-term trend for Avanos Medical's acquired in-process research and development?
- Over 4 years (2021 to 2025), Avanos Medical's acquired in-process research and development has grown at a -6.6% compound annual growth rate (CAGR), from $30.6M to $23.3M.
- What does acquired in-process research and development mean?
- Represents cash outflows for the acquisition of research and development projects that have not yet reached technological feasibility. This metric highlights the company's strategy for inorganic innovation and long-term pipeline expansion.